Precision has agreed to develop for Novartis a single custom ARCUS sequence-specific DNA-cutting enzyme, or nuclease, designed to insert in vivo, a therapeutic transgene at an undisclosed “safe harbor” location in the genome where a new gene can be added without otherwise affecting the patient’s DNA of gene expression patterns. Precision has agreed to issue an exclusive license for the custom ARCUS nuclease to Novartis for further development . . .
See More on the Edge
Continue reading this article and more
with a GEN Edge subscription
The post Beyond CRISPR: Precision Bio Lands Up-to-$1.5B Editing Deal with Novartis appeared first on GEN – Genetic Engineering and Biotechnology News.
